Todd Harrison Discusses Biopharmaceutical Investments

[Guest]

Bloomberg Opinion columnist Barry Ritholtz interviews Todd Harrison, a founding partner and chief investment officer at the hedge fund CB1 Capital, which focuses on cannabinoid-based solutions and biopharmaceutical applications and therapies. Prior to his work with CB1 Capital, Harrison spent almost three decades on Wall Street managing risk and researching financial market strategies. He was also the founder and CEO of Minyanville Media Inc., an Emmy-winning financial media company covering global markets in real time.

v3.mp3

https://www.bloomberg.com/news/audio/2018-06-28/todd-harrison-discusses-biopharmaceutical-investments

[Guest]

He mentions the 500 Cannabis related stocks and says 50 are worth investing in of which he wants to hold 25.

Wouldn't we all love to know which 25 those were!

He mentioned this company a few times:

GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.[4] Another cannabis-based product, Epidiolex, for treatment of epilepsy, was approved for treatment of epilepsy in 2018.

[Money & Finance]

@Lindsey Krewson This podcast above really educated me regarding .....